Age (years, mean ± SEM; range) |
63.16 ± 1.28; 18–89 |
Gender (n, %) |
|
male |
53 (54%) |
female |
46 (46%) |
End-stage renal disease underlying disease (n, %) |
|
glomerular diseases |
25 (25%) |
diabetic nephropathy |
15 (15%) |
nephrosclerosis |
15 (15%) |
polycystic kidney |
14 (14%) |
congenital nephropathies |
1 (1%) |
pyelonephritis |
5 (5%) |
hypertensive nephropathy |
7 (7%) |
others |
9 (9%) |
unknown |
10 (10%) |
Type of MRD (n, %) |
|
hemodialysis |
90 (91%) |
peritoneal dialysis |
9 (9%) |
Duration of MRD (years, mean ± SEM) |
7.91 ± 0.71 |
Duration of xerosis (years, mean ± SEM) |
5.4 ± 0.53 |
Clinical severity of xerosis (n, %) |
|
mild |
2 (2%) |
moderate |
50 (51%) |
severe to very severe |
47 (47%) |
Total clinical score of xerosis (mean ± SEM) |
8.3 ± 0.3 |
Association with pruritus (n, %) |
|
yes |
74 (75%) |
no |
25 (25%) |
Severity of pruritus (mm VAS, mean ± SEM) |
40.64 ± 3.36 |
Quality of life scores (mean ± SEM) |
|
PCS |
30.51 ± 1.21 |
MCS |
41.29 ± 1.24 |
DLQI |
5.61 ± 0.57 |